Company intelligence / Profile preview

Junevity

San Francisco, California, United Statesblog.junevity.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Junevity is developing siRNA therapeutics targeting transcription factors to reset aged or damaged cells to a healthier state. The company has demonstrated promising early data in preclinical models and is using its RESET platform, which leverages large-scale human data and AI, to identify novel targets for age-related diseases such as obesity, type 2 diabetes, and frailty. Seed funding will be used to advance the platform and develop initial therapeutic candidates.[3][6]

Therapeutic areas: OtherEndocrinologyNeurology
Modalities: siRNA therapeutics[1][3][4]
Industry: Biotech

Partnerships

UCSF Office of Technology Management & Advancement (exclusive license for core technology)[3]Advisory relationship with Brent Saunders (CEO/chairman Bausch + Lomb)[3]

Beyond the preview

Go deeper on Junevity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Junevity.

Explore the full profile